TARBP1 Inhibitors
TARBP1 inhibitors encompass a diverse array of chemical compounds designed to decrease the activity of TARBP1 by selectively targeting various cellular signaling pathways in which TARBP1 plays a crucial role. Stattic, as a STAT3 inhibitor, indirectly impairs the regulatory effect TARBP1 exerts on STAT3, thereby potentially diminishing TARBP1's role in cellular processes influenced by STAT3 signaling. Similarly, LY 294002 and Wortmannin, both inhibitors of PI3K, could result in a reduction of TARBP1 activity due to the protein's involvement in PI3K-mediated pathways. Rapamycin, targeting mTOR signaling which is modulated by TARBP1, could indirectly lessen the protein's functional activity. PD 98059 and U0126, which selectively inhibit MEK1/2, could also attenuate TARBP1's activity by modulating the MAPK pathway, a crucial signaling route that TARBP1 is known to influence.
Moreover, SB 203580, a p38 MAPK inhibitor, and SP600125, a JNK pathway inhibitor, could suppress TARBP1's role in these respective signaling cascades, leading to reduced functional activity of the protein. PP 2, by inhibiting Src family kinases, and Y-27632, as a ROCK inhibitor, could both indirectly lead to a decrease in TARBP1 function by targeting kinases that are upstream or regulatory components of pathways involving TARBP1. NF449, which antagonizes the Gs alpha subunit, may disrupt G-protein-coupled receptor signaling, thereby potentially reducing TARBP1 activity. Lastly, BAY 11-7082, by inhibiting NF-kB activation, could indirectly affect TARBP1's activity, considering NF-kB's interaction with pathways that encompass TARBP1. These inhibitors, through their targeted action on specific signaling molecules and pathways, collectively contribute to the diminished functional activity of TARBP1 without directly altering its expression levels.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Stat3 inhibitor V, stattic | 19983-44-9 | sc-202818 sc-202818A sc-202818B sc-202818C sc-202818D sc-202818E sc-202818F | 25 mg 100 mg 250 mg 500 mg 1 g 2.5 g 5 g | $130.00 $196.00 $274.00 $512.00 $731.00 $1408.00 $2091.00 | 114 | |
Stattic is a selective inhibitor of STAT3, a transcription factor. TARBP1 has been implicated in regulating STAT3 signaling. Inhibition of STAT3 by Stattic could diminish TARBP1's regulatory effect on this transcription factor, leading to decreased TARBP1 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a phosphoinositide 3-kinase (PI3K) inhibitor. PI3K signaling affects many cellular processes including those regulated by TARBP1. By inhibiting PI3K, LY 294002 could indirectly lead to reduced functional activity of TARBP1 through these pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor, and mTOR signaling has been shown to be influenced by TARBP1. By inhibiting mTOR, Rapamycin might indirectly reduce the functional activity of TARBP1 associated with this pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a MEK inhibitor, which is upstream of ERK/MAPK signaling. TARBP1 interacts with components of the MAPK signaling pathway, and inhibition of MEK by PD 98059 could therefore lead to a decrease in TARBP1 functional activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a p38 MAPK inhibitor. TARBP1 is known to be involved in pathways that include p38 MAPK. Inhibiting p38 MAPK with SB 203580 could suppress TARBP1's role in these signaling events. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP 2 is an Src family kinase inhibitor. Src kinases can influence TARBP1 activity, and by inhibiting these kinases, PP 2 could indirectly lead to a decrease in TARBP1 function. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a ROCK inhibitor, and ROCK signaling can impact the pathways where TARBP1 is involved. Inhibition of ROCK by Y-27632 might diminish the role of TARBP1 in these pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK. JNK signaling influences the functional activity of TARBP1. By inhibiting JNK, SP600125 could contribute to the decreased activity of TARBP1. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor. Given the role of PI3K in pathways involving TARBP1, its inhibition by Wortmannin is likely to reduce TARBP1's functional activity. | ||||||
NF449 | 627034-85-9 | sc-478179 sc-478179A sc-478179B | 10 mg 25 mg 100 mg | $203.00 $469.00 $1509.00 | 1 | |
NF449 is a Gs alpha subunit-specific antagonist, which can influence multiple signaling pathways including those regulated by TARBP1. By antagonizing Gs alpha, NF449 could decrease TARBP1 activity. | ||||||